李勇 研究員
膜受體調(diào)控與疾病研究組
辦公室地址：上海市重慶南路280號(hào)西7號(hào)樓305室
辦公室電話：021-63846590-778995
郵 箱：liyong68@shsmu.edu.cn
實(shí)驗(yàn)室地址：上海市重慶南路280號(hào)西7號(hào)樓304室
實(shí)驗(yàn)室電話：021-63846590-776448
研究方向
膜受體調(diào)控與疾病研究組以闡述蛋白質(zhì)翻譯后修飾(尤其是SUMO/deSUMO修飾)在膜受體內(nèi)質(zhì)網(wǎng)質(zhì)量控制和膜轉(zhuǎn)運(yùn)過程調(diào)控的分子機(jī)制及其與重大腦疾病的關(guān)系為目標(biāo)，致力于揭示翻譯后修飾在調(diào)控重要膜受體轉(zhuǎn)運(yùn)和調(diào)控的結(jié)構(gòu)基礎(chǔ)、蛋白相互作用及其生理學(xué)功能和病理學(xué)意義，探索針對(duì)膜受體功能異常的疾病防治策略。研究?jī)?nèi)容包括：
1）蛋白質(zhì)翻譯后修飾（尤其是SUMO/deSUMO）在痛癢覺調(diào)控中的作用和機(jī)制；
2）蛋白質(zhì)翻譯后修飾（尤其是SUMO/deSUMO）在成年神經(jīng)元凋亡中的作用和機(jī)制；
3）蛋白質(zhì)翻譯后修飾（尤其是SUMO/deSUMO）在精神神經(jīng)系統(tǒng)疾病（焦慮、抑郁等）中的作用和機(jī)制。
個(gè)人簡(jiǎn)歷
李勇，博士、特聘教授、博士生導(dǎo)師。1999年畢業(yè)于徐州醫(yī)科大學(xué)生物化學(xué)與分子生物學(xué)專業(yè)獲碩士學(xué)位，2003年畢業(yè)于中國(guó)科學(xué)技術(shù)大學(xué)生命科學(xué)學(xué)院神經(jīng)生物學(xué)專業(yè)獲博士學(xué)位。2003-2009年分別在美國(guó)麻省理工學(xué)院和阿拉巴馬大學(xué)伯明翰醫(yī)學(xué)院從事博士后研究。2009年至今在上海交通大學(xué)醫(yī)學(xué)院基礎(chǔ)醫(yī)學(xué)院，生化與分子細(xì)胞生物學(xué)系“膜受體調(diào)控與疾病”研究組任課題組長(zhǎng)(PI)，教授及博士生導(dǎo)師，曾任神經(jīng)生物學(xué)教研室主任(2009-2011年)，2018年入選醫(yī)學(xué)院特聘教授。課題組長(zhǎng)期從事膜受體轉(zhuǎn)運(yùn)調(diào)控與疾病關(guān)系研究, 特別關(guān)注重要神經(jīng)信號(hào)蛋白SUMO/deSUMO動(dòng)態(tài)修飾在神經(jīng)系統(tǒng)離子通道和受體中的作用及其分子基礎(chǔ)的研究。已在Neuron、Sci Adv、Nat Commun、J Neurosci、JBC等國(guó)際學(xué)術(shù)期刊發(fā)表30篇學(xué)術(shù)論文。已畢業(yè)博士15人,碩士3人。現(xiàn)指導(dǎo)博士后1人和碩、博生10人，聯(lián)合培養(yǎng)生碩博生3人。是中國(guó)神經(jīng)科學(xué)離子通道與受體分會(huì)副主任委員和上海神經(jīng)科學(xué)學(xué)會(huì)常務(wù)理事。承擔(dān)國(guó)家基金委重點(diǎn)、國(guó)際(地區(qū))合作與交流項(xiàng)目、科技部國(guó)家重點(diǎn)研發(fā)計(jì)劃子課題、科技部2030重大項(xiàng)目子課題、面上項(xiàng)目、上海市市級(jí)科技重大專項(xiàng)子課題、上海市基礎(chǔ)研究重點(diǎn)等項(xiàng)目。擔(dān)任國(guó)際學(xué)術(shù)期刊《Brain Behavior and Immunity》和《Frontiers in Pharmacology》編委。
科研項(xiàng)目
【1】2021ZD0203100 感知覺與情緒相互作用的神經(jīng)環(huán)路機(jī)制 科技部2030重大項(xiàng)目 2021-12~2026-11 263萬元 子課題參與人
【2】待更新 阿爾茨海默病發(fā)病機(jī)制及相關(guān)創(chuàng)新藥的研究 上海市市級(jí)科技重大專項(xiàng) 2021-06~2025-12 500萬元 子課題負(fù)責(zé)人
【3】2020YFA0803600 組織器官代謝可塑性與記憶的調(diào)控機(jī)制及其生理病理意義 科技部國(guó)家重點(diǎn)研發(fā)計(jì)劃 2020-12~2025-11 140.84萬元 子課題負(fù)責(zé)人
【4】82071510 Cofilin SUMO/deSUMO動(dòng)態(tài)修飾調(diào)控機(jī)制及其在焦慮中的作用 國(guó)家自然基金面上項(xiàng)目 2021-01~2024-12 55萬元 課題負(fù)責(zé)人
【5】31830031 SUMO/deSUM修飾在痛癢覺調(diào)控中的作用和機(jī)制 國(guó)家自然基金重點(diǎn)項(xiàng)目 2019-01~2023-12 284萬元 課題負(fù)責(zé)人
【6】31761163002 SENP3在自閉癥中的作用和機(jī)制 國(guó)家自然基金國(guó)際(地區(qū))合作與交流項(xiàng)目 2018-01~2020-12 195萬元 課題負(fù)責(zé)人
【7】31671053 TRPV1 SUMO/deSUMO修飾調(diào)控膜轉(zhuǎn)運(yùn)及其在痛覺調(diào)控中的作用 國(guó)家自然基金面上項(xiàng)目 2017-01~2020-12 62萬元 課題負(fù)責(zé)人
【8】31371064 SUMO/DeSUMO化修飾在抑制性受體膜轉(zhuǎn)運(yùn)中的作用 國(guó)家自然基金面上項(xiàng)目 2014-01~2017-12 85萬元 課題負(fù)責(zé)人
【9】2014CB910303 重要新型膜離子通道的生理和藥理功能 科技部國(guó)家重大科學(xué)研究計(jì)劃項(xiàng)目 2014-01~2018-12 120萬元 子課題負(fù)責(zé)人
【10】81171230 內(nèi)源性BDNF在Rett綜合癥中的作用研究 國(guó)家自然基金面上項(xiàng)目 2012-01~2015-12 60萬元 主要責(zé)任人
【11】91132303 情感和記憶調(diào)控的抑制性神經(jīng)環(huán)路機(jī)制 國(guó)家自然科學(xué)基金重大研究計(jì)劃/重點(diǎn)支持項(xiàng)目 2012-01~2015-12 100萬元 課題參與人
【12】11PJ1406100 甘氨酸受體膜轉(zhuǎn)運(yùn)調(diào)節(jié)機(jī)制 上海市科委浦江人才項(xiàng)目 2011-01~2013-12 20萬元 課題負(fù)責(zé)人
【13】30970937 14-3-3蛋白調(diào)控CaV2.2通道膜轉(zhuǎn)運(yùn)及其機(jī)制研究 國(guó)家自然基金面上項(xiàng)目 2010-01~2012-12 35萬元 課題負(fù)責(zé)人
【14】2010CB912001 神經(jīng)元信息感受重要蛋白質(zhì)膜轉(zhuǎn)運(yùn)的結(jié)構(gòu)基礎(chǔ)、調(diào)控及功能研究 科技部國(guó)家重大科學(xué)研究計(jì)劃子項(xiàng)目 2010-01~2014-12 135萬元 子課題負(fù)責(zé)人
【15】09JC1408700 14-3-3蛋白調(diào)控CaV2.2通道膜轉(zhuǎn)運(yùn)及其機(jī)制研究 上海市科委"創(chuàng)新行動(dòng)計(jì)劃"基礎(chǔ)研究重點(diǎn)項(xiàng)目 2009-09~2011-08 30萬元 課題負(fù)責(zé)人
論文與專著
1. Qiao Zhang*, Weiji Weng*, Xiaokun Gu*, Jinhua Xiang, Yang Yang, Michael X Zhu, Weidong Gu#, Zhenzhou He#, Yong Li#. hnRNPA1 SUMOylation promotes cold hypersensitivity in chronic inflammatory pain by stabilizing TRPA1 mRNA. Cell Reports, 2023 Nov 28;42(11):113401.
2. Weiji Weng*, Xiaokun Gu*, Yang Yang*, Qiao Zhang, Qi Deng, Jie Zhou, Jinke Cheng, Michael X. Zhu, Junfeng Feng#, OuHuang#, Yong Li#. N-terminal α-amino SUMOylation of cofilin-1 is critical for its regulation of actin depolymerization. Nature Communications, 2023 Sep 14;14(1):5688.
3. Yingwei Gao*, Ruining Ma*, Weiji Weng*, Heng Zhang, Yingping Wang, Rongjun Guo, Xiaokun Gu, Yang Yang, Fan Yang, Aiwu Zhou, Jinke Cheng, Zhe-Yu Chen#, Michael X Zhu#, Yong Li#. TRPV1 SUMOylation suppresses itch by inhibiting TRPV1 interaction with H1 receptors. Cell Reports, 2022 Jun 14;39(11):110972.
4. Siman Gao, Xiangteng Zhao, Lin Hou, Ruining Ma, Jie Zhou, Michael X. Zhu, Si-Jian Pan, Yong Li. The interplay between SUMOylation and phosphorylation of PKCd facilitates oxidative stress-induced apoptosis.The FEBS Journal, 2021, 288(22):6447-6464.
5.Xiangteng Zhao, Bianbian Xia, Jinke Cheng, Michael X Zhu, Yong Li. PKC epsilon SUMOylation Is Required for Mediating the Nociceptive Signaling of Inflammatory Pain. Cell Reports, 2020, 33(1):108191.
6. Huiqing Liu*, Weiji Weng*, Rongjun Guo*, Jie Zhou, Jun Xue , Shan Zhong , Jinke Cheng, Michael X Zhu, Si-Jian Pan#, Yong Li #. Olig2 SUMOylation protects against genotoxic damage response by antagonizing p53 gene targeting. Cell Death and Differentiation, 2020, 27(11):3146-3161.
7. Dehua Huang, Huiqing Liu, Aoxue Zhu, Yi Zhou, Yong Li. Forebrain excitatory neuron-specific SENP2 knockout mouse displays hyperactivity, impaired learning and memory, and anxiolytic-like behavior. Molecular Brain, 2020, 13(1):59.
8. Ruining Ma*, Lina Ma*, Weiji Weng*, Yingping Wang, Huiqing Liu, Rongjun Guo, Yingwei Gao, Jun Tu, Tian-Le Xu, Jinke Cheng, Michael X Zhu, Aiwu Zhou#, Yong Li#. DUSP6 SUMOylation protects cells from oxidative damage via direct regulation of Drp1 dephosphorylation. Science Advances, 2020, 6(13):eaaz0361.
9. Yan Wang*, Yingwei Gao*, Quan Tian*, Qi Deng, Yangbo Wang, Tian Zhou, Qiang Liu, Kaidi Mei, Yingping Wang, Huiqing Liu, Ruining Ma, Yuqiang Ding, Weifang Rong, Jinke Cheng, Jing Yao, Tian-Le Xu, Michael X Zhu, Yong Li. TRPV1 SUMOylation regulates nociceptive signaling in models of inflammatory pain. Nature Communications, 2018, 9(1):1529. (highlighted in “Faculty of 1000”, 2018).
10. Xiaoling Li*, Yan Wang, Aoxue Zhu, Jie Zhou, Yong Li. PKC SUMOylation inhibits the binding of 14-3-3τ to GluK2. Channels (Austin), 2017, 11(6):616-623.
11. Huijun Zhang*, Yan Wang*, Aoxue Zhu*, Dehua Huang*, Shining Deng, Jinke Cheng, Michael X Zhu, Yong Li. SUMO-specific protease 1 protects neurons from apoptotic death during transient brain ischemia/reperfusion. Cell Death and Disease, 2016, 7, e2484.
12. Yan Wang*, Yangbo Wang*, Huijun Zhang*, Yingwei Gao, Chao Huang, Aiwu Zhou, Yi Zhou, Yong Li. Sequential posttranslational modifications regulate PKC degradation. Molecular Biology of the Cell, 2016, 27:410-420.
13. Feng Liu*, Qin Zhou*, Jie Zhou*, Hao Sun, Yan Wang, Xiuqun Zou, Lingling Feng, Zhaoyuan Hou, Aiwu Zhou, Yi Zhou, Yong Li. 14-3-3τ promotes surface expression of Cav2.2 (α1B) Ca2+ channels. Journal of Biological Chemistry, 2015, 290(5):2689-2698.
14. Hao Sun*, Li Lu*, Yong Zuo*, Yan Wang, Yingfu Jiao, Wei-Zheng Zeng, Chao Huang, Michael X Zhu, Gerald W Zamponi, Tong Zhou, Tian-Le Xu, Jinke Cheng, Yong Li. Kainate receptor activation induces glycine receptor endocytosis through PKC deSUMOylation. Nature Communications, 2014, 5:4980.
15. Changcheng Sun*, Haifa Qiao*, Qin Zhou, Yan Wang, Yuying Wu, Yi Zhou, Yong Li. Modulation of GluK2a Subunit-containing kainate receptors by 14-3-3 Proteins. Journal of Biological Chemistry, 2013, 288:24676-24690.
16. Chen Huang*, Wei-Guang Li*, Xiao-Bing Zhang, Li Wang, Tian-Le Xu, Dazheng Wu#, Yong Li. Alpha-asarone from Acorus gramineusalleviates epilepsy by modulating A-Type GABA receptors. Neuropharmacology. 2013, 65:1-11.
17. Li Wang, Wei-Guang Li, Chen Huang, Michael X Zhu, Tian-Le Xu, Da-Zheng Wu#, Yong Li#. Subunit-specific inhibition of glycinereceptors by curcumol. Journal of Pharmacology and Experimental Therapeutics. 2012, 343(2):371-9.
18. Yong Li*, Xinqiu Liu*, Yuying Wu*, Zhe Xu, Hongqin Li, Leslie C Griffith, Yi Zhou. Intracellular regions of the Eag potassiumchannel play a critical role in generation of voltage-dependent currents. Journal of Biological Chemistry. 2011,286(2):1389-99.
19. Yong Li, Gaston Calfa, Takafumi Inoue, Michelle D Amaral, Lucas Pozzo-Miller. Activity-dependent release of endogenous BDNF from mossy fibers evokes a TRPC3 current and Ca2+ elevations in CA3 pyramidal neurons, Journal of Neurophysiology. 2010, 103(5):2846-56.
20. Roujian Lu*, Yong Li*, Youwen Zhang*, Yunjia Chen, Angela D Shields, Danny G Winder, Timothy Angelotti, Kai Jiao, Lee E Limbird, Yi Zhou, Qin Wang. Epitope-tagged receptor knock-in mice reveal that differential desensitization of alpha2-adrenergic responses is because of ligand-selective internalization. Journal of Biological Chemistry. 2009, 284(19):13233-43.
21. Yong Li, Yuying Wu, Rui Li, Yi Zhou. The role of 14-3-3 dimerization in its modulation of the CaV2.2 Channel. Channels (Austin). Jan-Feb 2007;1(1):1-2.
22. Yong Li, Yuying Wu, Yi Zhou. Modulation of inactivation properties of CaV2.2 channels by 14-3-3 proteins. Neuron. 2006 Sep 21;51(6):755-71.
23. Yong Li, Long-Jun Wu, Pascal Legendre, Tian-Le Xu. Asymmetric cross-inhibition between GABAA and glycine receptors in rat spinal dorsal horn neurons. Journal of Biological Chemistry. 2003 Oct 3;278(40):38637-45.
24. Yong Li, Yan-Fang Li, Tian-Le Xu. Amiloride inhibition of glycinergic mIPSCs in mechanically dissociated rat spinal neurons. Neuroscience Letters. 2003 Sep 25;349(1):17-20.
25. Yong Li, Tian-Le Xu. State-dependent cross-inhibition between anionic GABA(A) and glycine ionotropic receptors in rat hippocampal CA1 neurons. Neuroreport. 2002 Feb 11;13(2):223-6.
26. Lin Pei, Yong Li, Guangyi Zhang, Zhaochun Cui, Zhengmei Zhu. Mechanisms of regulation of tyrosine phosphorylation of NMDA receptor subunit 2B after cerebral ischemia/reperfusion. Acta Pharmacologica Sinica. 2000 Aug;21(8):695-700.
27. Lin Pei, Yong Li, Jingzhi Yan, Guangyi Zhang, Zhaochun Cui, Zhengmei Zhu. Changes and mechanisms of protein-tyrosine kinase and protein-tyrosine phosphatase activities after brain ischemia/reperfusionsubunit 2B after cerebral ischemia/reperfusion.Acta Pharmacologica Sinica. 2000 Aug;21(8):715-20.
